1 completed, 1 terminated, 1 withdrawn. 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow AVN 944: new trials by email Literature Review of AVN 944 trials Research Report on AVN 944
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors AVN944 - Refractory Solid Tumors | Not applicable | Withdrawn | Vertex Pharmaceuticals Incorporated | 2009-04-01 | 2014-01-10 | |
| AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer AVN944 - Pancreatic Cancer | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 28 | 2007-06-01 | 2020-09-30 |
| Trial of AVN-944 in Patients With Advanced Hematologic Malignancies AVN-944 capsules for oral administration - Acute Leukemia, Chronic Leukemia | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 72 | 2006-01-01 | 2011-08-04 |
Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Waldenstrom Macroglobulinemia (1)
Vertex Pharmaceuticals Incorporated (3)
United States (3)